帕金森氏症治療市場：按藥物類別、給藥途徑、分銷管道和地區分類

Parkinsons Disease Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，帕金森氏症治療市場規模將達到 62.7 億美元，到 2033 年將達到 102 億美元。預計 2026 年至 2033 年的複合年成長率將達到 7.2%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	62.7億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	7.20%	2033年市場規模預測：	102億美元

帕金森氏症是一種由神經系統疾病引起的運動障礙。常見症狀包括震顫、運動遲緩、肌肉僵硬、步態不穩、平衡和協調能力受損。左旋多巴、多巴胺促效劑、MAO-B抑制劑和抗膽鹼能藥物是治療帕金森氏症的常用藥物。左旋多巴（也稱為L-多巴）是治療帕金森氏症最常使用的藥物，能有效控制運動遲緩和肌肉僵硬等症狀。透過藥物治療，大多數患者可以維持較高的生活品質，在某些情況下，手術也能改善症狀。帕金森氏症患者體內另一種名為去甲腎上腺素的神經傳導物質也會減少。這種分子對於交感神經系統的正常功能至關重要。自主神經系統控制體內的一些活動，例如消化、心率、血壓和呼吸。帕金森氏症的一些非運動症狀是由去甲腎上腺素缺乏引起的。運動可以顯著改善帕金森氏症的症狀。物理治療、職能治療和語言治療也有助於改善行走和平衡問題、進食和吞嚥困難以及言語障礙。

市場動態

市場新進業者正致力於推出新產品，預計將推動帕金森氏症治療市場在預測期內的成長。例如，2020年5月，製藥公司Sunovion Pharmaceuticals Inc.宣布，其KYNMOBI（鹽酸阿撲嗎啡）舌下膜已獲得美國食品藥物管理局）批准，用於治療帕金森氏症患者的「關期」（即帕金森氏症症狀的複發或加重）的急性期和間歇期。 KYNMOBI有多種劑量規格，包括10毫克、15毫克、20毫克和25毫克。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數，對全球帕金森氏症治療市場的主要公司進行了概況介紹：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份《全球帕金森氏症治療市場》報告旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球帕金森氏症治療市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

公司簡介
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- GlaxoSmithKline Plc.
- AbbVie Inc.
- Merck & Co., Inc.
- Zydus Cadila
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Boehringer Ingelheim International GmbH
- Denali Therapeutics Inc.
- Biogen Inc.
- Prevail Therapeutics
- Eli Lilly and Company
- Voyager Therapeutics

第9章

參考
調查方法

簡介目錄

Product Code: CMI494

Parkinsons Disease Therapeutics Market is estimated to be valued at USD 6.27 Bn in 2026 and is expected to reach USD 10.20 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 6.27 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.20%	2033 Value Projection:	USD 10.20 Bn

Parkinson's disease is a movement disorder caused by a neurological condition. Tremor, slowness of movement, tight muscles, an unsteady walk, balance, and coordination issues are all common symptoms. Levodopa, Dopamine agonists, MAO-B inhibitors, and Anticholinergics are some of the medications used for the treatment of Parkinson's disease. Levodopa (also called L-dopa) is the most commonly prescribed drug for Parkinson's disease. It is useful in controlling the symptoms such as slow movements and stiff & rigid body parts. Medication allows the majority of patients to retain a high quality of life and surgery can help some people improve their symptoms. Parkinson's disease patients also observe decrease in another neurotransmitter known as norepinephrine. This molecule is required for the sympathetic nervous system to operate properly. Some of the body's autonomic activities are controlled by this system, including digestion, heart rate, blood pressure, and breathing. Some of the non-movement-related symptoms of Parkinson's disease are caused by a lack of norepinephrine. Exercise can considerably improve Parkinson's symptoms. Physical therapy, occupational therapy, and speech-language therapy can also assist with walking and balance issues, eating and swallowing difficulties, and speech disorders.

Market Dynamics

Market players are focusing on new product launches, which is expected to propel the Parkinson's disease therapeutic market growth during the forecast period. For instance, in May 2020, Sunovion Pharmaceuticals Inc. a pharmaceutical company announced that it received the U.S. Food and Drug Administration (FDA) approval for KYNMOBI (apomorphine hydrochloride) Sublingual Film for the acute, intermittent treatment for OFF episodes (i.e. re-emergence or worsening of PD symptoms) in patients with Parkinson's disease. KYNMOBI is available in different strengths such as 10mg, 15mg, 20mg, and 25mg.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Parkinson's disease therapeutic market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., and Boehringer Ingelheim International GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Parkinson's disease therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global Parkinson's disease therapeutic market

Detailed Segmentation:

Global Parkinson's Disease Therapeutic Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
Levodopa
Dopamine agonists
MAO-B inhibitors
Anticholinergics
Others
Global Parkinson's Disease Therapeutic Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
Oral
Injectable
Nasal
Transdermal
Others
Global Parkinson's Disease Therapeutic Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Parkinson's Disease Therapeutic Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- By Drug Class
  - Levodopa
- By Route of Administration
  - Oral
  - Injectable
  - Nasal
  - Transdermal
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - U.S.
  - Canada
Latin America
- By Drug Class
  - Levodopa
- By Route of Administration
  - Oral
  - Injectable
  - Nasal
  - Transdermal
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Drug Class
  - Levodopa
- By Route of Administration
  - Oral
  - Injectable
  - Nasal
  - Transdermal
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Drug Class
  - Levodopa
- By Route of Administration
  - Oral
  - Injectable
  - Nasal
  - Transdermal
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Drug Class
  - Levodopa
- By Route of Administration
  - Oral
  - Injectable
  - Nasal
  - Transdermal
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Drug Class
  - Levodopa
- By Route of Administration
  - Oral
  - Injectable
  - Nasal
  - Transdermal
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country/Region
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Teva Pharmaceutical Industries Ltd.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
Novartis AG
GlaxoSmithKline Plc.
AbbVie Inc.
Merck & Co., Inc.
Zydus Cadila
Reddy's Laboratories
Sun Pharmaceutical Industries Ltd.
Cipla Inc.
Boehringer Ingelheim International GmbH

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4 Global Parkinsons Disease Therapeutics Market, By Drug Class, 2021- 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Levodopa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Dopamine agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
MAO-B inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Anticholinergics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine, among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends

5 Global Parkinsons Disease Therapeutics Market, By Route of Administration, 2021-2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Others (Rectal, Sublingual, among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends

6 Global Parkinsons Disease Therapeutics Market, By Distribution Channel, 2021-2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)

7 Global Parkinsons Disease Therapeutics Market, By Region, 2021-2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- 'Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2021 -2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

8 Competitive Landscape

Company Profiles
- Teva Pharmaceutical Industries Ltd.*
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- GlaxoSmithKline Plc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AbbVie Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Merck & Co., Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Zydus Cadila
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Dr. Reddy's Laboratories
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sun Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Cipla Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Boehringer Ingelheim International GmbH
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Denali Therapeutics Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Biogen Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Prevail Therapeutics
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eli Lilly and Company
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Voyager Therapeutics
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies